SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
-15.44%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$155M
AUM Growth
+$155M
(-52%)
Cap. Flow
-$111M
Cap. Flow
% of AUM
-71.71%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
1
Reduced
3
Closed
1
Top Buys
| 1 |
Lantheus
LNTH
|
$3.61M |
Top Sells
| 1 |
Innoviva
INVA
|
$80.9M |
| 2 |
Gilead Sciences
GILD
|
$24.2M |
| 3 |
Cytokinetics
CYTK
|
$9.4M |
| 4 |
Vor Biopharma
VOR
|
$78.9K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Innoviva
INVA
$1.29B
| $51.1M | 33% | 2,816,022 -4,460,978 | -61% | -$80.9M |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $34.2M | 22.1% | 309,116 | – | – |
|
|
3
Cytokinetics
CYTK
$4.23B
| $24.1M | 15.59% | 600,000 -233,799 | -28% | -$9.4M |
|
4
Ironwood Pharmaceuticals
IRWD
$214M
| $24.1M | 15.57% | 16,390,000 | – | – |
|
|
AMRN
5
Amarin Corp
AMRN
$311M
| $11.1M | 7.2% | 24,850,623 | – | – |
|
|
6
Lantheus
LNTH
$3.73B
| $9.76M | 6.31% | 100,000 +37,000 | +59% | +$3.61M |
|
|
7
Vor Biopharma
VOR
$250M
| $365K | 0.24% | 508,016 -109,984 | -18% | -$78.9K |
|
|
8
Gilead Sciences
GILD
$140B
| – | – | -262,080 | Closed | -$24.2M |
|